Publications by authors named "K Kaku"

Introduction: An increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This post-hoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.

Materials And Methods: Data were derived from the 52-week, open-label, phase 3 TIMES-2 trial in Japanese type 2 diabetes patients.

View Article and Find Full Text PDF

Objective Immune checkpoint inhibitor-associated hypopituitarism (ICI-HP) is a rare immune-related adverse event (irAE) of ICIs. This study aimed to identify characteristic pituitary findings on magnetic resonance imaging (MRI) in ICI-HP. Methods This study is a single-center, retrospective, observational study.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to compare the effects of two diabetes medications, SGLT2 inhibitors (luseogliflozin) and DPP-4 inhibitors (teneligliptin), on β-cell function in type 2 diabetes patients over 26 weeks.
  • A total of 103 participants were included, with results showing improvements in the disposition index (a measure of insulin effectiveness) for both groups, but with more significant alleviation of β-cell dysfunction in the luseogliflozin group.
  • The findings suggest that while both drugs improve insulin secretion and sensitivity, luseogliflozin may be more effective at reducing β-cell dysfunction compared to teneligliptin.*
View Article and Find Full Text PDF

Introduction: Histopathological findings of chronic active T-cell-mediated rejection (CA-TCMR) have been reported to potentially improve with treatment. However, whether this improvement is associated with a better renal prognosis remains unclear. This study was performed to analyze the impact of the histological response to therapy on kidney allograft survival in patients with CA-TCMR.

View Article and Find Full Text PDF

Aim Chronic hyperglycemia is a well-known risk factor for the development of many macrovascular complications, but hyperglycemia may be reportedly protective against abdominal aneurysms. Materials and methods In this study, we evaluated morphological differences in the abdominal aorta between subjects with and without type 2 diabetes mellitus (T2DM) without abdominal aortic aneurysm and evaluated the correlation between imaging findings of computed tomography (CT) and diabetes-related parameters. Results The abdominal aortic diameter was significantly smaller in subjects with T2DM compared to non-diabetes mellitus (NDM) subjects (p=0.

View Article and Find Full Text PDF